Cancer research network: Using integrated healthcare delivery systems as platforms for cancer survivorship research

Journal of Cancer Survivorship

Volumn 7, Issue 1, 2013, Pages 55-62

  Nekhlyudov, Larissa ^a   Greene, Sarah M ^b   Chubak, Jessica ^b,c   Rabin, Borsika ^d   Tuzzio, Leah ^b   Rolnick, Sharon ^e   Field, Terry S ^f  

^a HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^b Research Institute   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d KAISER PERMANENTE   (United States)

^e HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

^f UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cancer survivorship; Heath services research; Integrated health care systems

Indexed keywords

EID: 84873746610     PISSN: 19322259     EISSN: 19322267     Source Type: Journal    
DOI: 10.1007/s11764-012-0244-8     Document Type: Review

References (71)

1. Institute of Medicine and National Research Council of the National Academies. From cancer patient to cancer survivor: lost in transition. Washington: The National Academies Press; 2006.
2. Field TS, Cernieux J, Buist DS, Geiger AM, Lamerato L, Hart G, et al. Retention of enrollees following a cancer diagnosis within health maintenance organizations in the Cancer Research Network. J Natl Cancer Inst. 2004; 96: 148-52.
3. Wagner EH, Greene SM, Hart G, Field TS, Fletcher S, Geiger AM, et al. Building a research consortium of large health systems: the Cancer Research Network. J Natl Cancer Inst Monogr. 2005; 35: 3-11.
4. Geiger AM, Buist DS, Greene SM, Altschuler A, Field T. Survivorship research based in integrated healthcare delivery systems: the Cancer Research Network. Cancer. 2008; 112: 2617-26.
5. The HMO Cancer Research Network: Capacity, Collaboration, and Investigation. http://crncancergov/publications/capacity_collaboration_investigation_2010_aprpdf2011 [accessed 2012 Mar 19].
6. Aiello Bowles EJ, Tuzzio L, Ritzwoller DP, Williams AE, Ross T, Wagner EH, et al. Accuracy and complexities of using automated clinical data for capturing chemotherapy administrations: implications for future research. Med Care. 2009; 47: 1091-7.
7. Delate T, Aiello Bowles EJ, Pardee R, Wellman RD, Habel LA, Yood MU, et al. Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiol Biomarkers Prev. 2012; 21: 673-80.
8. Ritzwoller DP, Carroll N, Delate T, O'Keeffe-Rossetti M, Fishman PA, Loggers ET, et al. Validation of electronic data on chemotherapy use in HMOs. Med Care. 2012. doi: 10. 1097/MLR. 0b013e31824def85.
9. Chubak J, Yu O, Pocobelli G, Lamerato L, Webster J, Prout MN, et al. Administrative data algorithms to identify second breast cancer events following early-stage invasive breast cancer. J Nat Cancer Inst. 2012; 104: 931-40.
10. Hazlehurst B, Sittig DF, Stevens VJ, Smith KS, Hollis JF, Vogt TM, et al. Natural language processing in the electronic medical record: assessing clinician adherence to tobacco treatment guidelines. Am J Prev Med. 2005; 29: 434-9.
11. Hazlehurst B, Frost HF, Sittig DF, Stevens VJ. MediClass: a system for detecting and classifying encounter-based clinical events in any electronic medical record. J Am Med Inform Assoc. 2005; 12: 517-29.
12. Avila CC, Quinn VP, Geiger AM, Kerby TJ, St. Charles M, Clough-Gorr KM. Webinar training: an acceptable, feasible and effective approach for multi-site medical record abstraction: the BOWII experience. BMC Res Notes. 2011; 4: 430.
13. Geiger AM, Greene SM, Pardee RE3, Hart G, Herrinton LJ, Macedo AM, et al. A computerized system to facilitate medical record abstraction in cancer research (United States). Cancer Causes Control. 2003; 14: 469-76.
14. Lash TL, Fox MP, Thwin SS, Geiger AM, Buist DS, Wei F, et al. Using probabilistic corrections to account for abstractor agreement in medical record reviews. Am J Epidemiol. 2007; 165: 1454-61.
15. Specimen collection within the CRN: a critical appraisal. http://crncancergov/publications/crn_specimen_collectionpdf2010 [accessed 2012 Mar 19].
16. Greene SM, Geiger AM, Harris EL, Altschuler A, Nekhlyudov L, Barton MB, et al. Impact of IRB requirements on a multicenter survey of prophylactic mastectomy outcomes. Ann Epidemiol. 2006; 16: 275-8.
17. Greene SM, Hart G, Wagner EH. Measuring and improving performance in multicenter research consortia. J Natl Cancer Inst Monogr. 2005; 35: 26-32.
18. Greene SM, Geiger AM. A review finds that multicenter studies face substantial challenges but strategies exist to achieve Institutional Review Board approval. J Clin Epidemiol. 2006; 59(8): 784-90.
19. Doubeni CA, Field TS, Yood MU, Rolnick SJ, Quesenberry CP, Fouayzi H, et al. Patterns and predictors of mammography utilization among breast cancer survivors. Cancer. 2006; 106: 2482-8.
20. Field TS, Doubeni CA, Fox MP, Buist DS, Wei F, Geiger AM, et al. Under utilization of surveillance mammography among older breast cancer survivors. J Gen Intern Med. 2008; 23: 158-63.
21. Nekhlyudov L, Habel LA, Achacoso NS, Jung I, Haque R, Collins LC, et al. Adherence to long-term surveillance mammography among women with ductal carcinoma in situ treated with breast-conserving surgery. J Clin Oncol. 2009; 27: 3211-6.
22. Lafata JE, Simpkins J, Schultz L, Chase GA, Johnson CC, Yood MU, et al. Routine surveillance care after cancer treatment with curative intent. Med Care. 2005; 43: 592-9.
23. Salz T, Weinberger M, Ayanian JZ, Brewer NT, Earle CC, Elston Lafata J, et al. Variation in use of surveillance colonoscopy among colorectal cancer survivors in the United States. BMC Health Serv Res. 2010; 10: 256-63.
24. Rolnick S, Hensley Alford S, Kucera GP, Fortman K, Ulcickas Yood M, Jankowski M, et al. Racial and age differences in colon examination surveillance following a diagnosis of colorectal cancer. J Natl Cancer Inst Monogr. 2005; 35: 96-101.
25. Salloum RG, Hornbrook MC, Fishman PA, Ritzwoller DP, O'Keeffe-Rossetti M, Elston-Lafata J. Adherence to surveillance care guidelines after breast and colorectal cancer treatment with curative intent. Cancer. 2012; 118(22): 5644-51.
26. Sox HC, Greenfield S. Comparative effectiveness research: a report from the Institute of Medicine. Annals Intern Med. 2009; 151: 203-5.
27. Bosco JL, Lash TL, Prout MN, Buist DS, Geiger AM, Haque R, et al. Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2979-83.
28. Field TS, Bosco JL, Prout MN, Gold HT, Cutrona S, Pawloski PA, et al. Age, comorbidity, and breast cancer severity: impact on receipt of definitive local therapy and rate of recurrence among older women with early-stage breast cancer. J Am Coll Surg. 2011; 213: 757-65.
29. Haque R, Yood MU, Geiger AM, Kamineni A, Avila CC, Shi J, et al. Long-term safety of radiotherapy and breast cancer laterality in older survivors. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2120-6.
30. Earle CC, Burstein HJ, Winer EP, Weeks JC. Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003; 21(8): 1447-51.
31. Earle CC, Neville BA. Under use of necessary care among cancer survivors. Cancer. 2004; 101: 1712-9.
32. Snyder CF, Frick K, Peairs K, Kantsiper M, Herbert R, Blackford A, et al. Comparing care for breast cancer survivors to non-cancer controls: a five-year longitudinal study. J Gen Intern Med. 2009; 24: 469-74.
33. Snyder CF, Earle CC, Herbert RJ, Neville BA, Blackford AL, Frick KD. Preventive care for colorectal cancer survivors: a 5-year longitudinal study. J Clin Oncol. 2008; 26: 1073-9.
34. Snyder CF, Frick KD, Kantsiper ME, Peairs KS, Herbert RJ, Blackford AL, et al. Prevention, screening, and surveillance care for breast cancer survivors compared with controls: changes from 1998 to 2002. J Clin Oncol. 2009; 27: 1054-61.
35. Snyder CF, Frick KD, Herbert RJ, Blackford AL, Neville BA, Carducci MA, et al. Preventive care in prostate cancer patients: following diagnosis and for five-year survivors. J Cancer Surviv. 2011; 5: 283-91.
36. Rowland JH, Mariotto A, Alfano CM, Pollack LA, Weir HK, White A. Cancer survivors-United States, 2007. MMMR. 2011; 60: 26-272.
37. The Kaiser Family Foundation. State Health Facts. http://www. statehealthfactsorg/comparebarjsp?ind=349&cat=7&sub=85&yr=194&typ=2&sort=a2011 [accessed 2012 Mar 19].
38. A National Coalition for Cancer Survivorship and Institute of Medicine National Cancer Policy Forum Workshop TLAFaTNCI. Implementing Cancer Survivorship Care Planning. Washington, D. C.: The National Academies Press; 2007.
39. Chubak J, Tuzzio L, Hsu C, Alfano CM, Rabin B, Hornbrook MC, et al. Providing care to cancer survivors in integrated healthcare delivery systems: practices, challenges, and research opportunities. J Oncol Pract. 2012; 8: 184-9.
40. Wagner EH, Aiello Bowles EJ, Greene SM, Tuzzio L, Wiese CJ, Kirlin B, et al. The quality of cancer patient experience: perspectives of patients, family members, providers and experts. Qual Saf Health Care. 2010; 19: 484-9.
41. Oeffinger KC, McCabe MS. Models for delivering survivorship care. J Clin Oncol. 2006; 24: 5117-24.
42. McCabe MS, Jacobs L. Survivorship care: models and programs. Semin Oncol Nurs. 2008; 24: 202-7.
43. Harrop JP, Dean JA, Paskett ED. Cancer survivorship research: a review of the literature and summary of current NCI-designated cancer center projects. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2042-7.
44. Stricker CT, Jacobs LA, Risendal B, Jones A, Panzer S, Ganz PA, et al. Survivorship care planning after the institute of medicine recommendations: how are we faring? J Cancer Surviv. 2011; 5: 358-70.
45. Noah-Vanhoucke J, Green LE, Dinh TA, Alperin P, Smith RA. Cost-effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population. Cancer. 2011; 117: 3322-31.
46. Skolarus TA, Zhang Y, Miller DC, Wei JT, Hollenbeck BK. The economic burden of prostate cancer survivorship care. J Urol. 2010; 184: 532-8.
47. Lux MP, Wöckel A, Benedict A, Buchholz S, Kreif N, et al. Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer-a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system. Onkologie. 2010; 33: 155-66.
48. Yabroff KR, Lund J, Kepka D, Mariotto A. Economic burden of cancer in the United States: estimates, projections, and future research. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2006-14.
49. Committee on Psychosocial Services to Cancer Patients/Families in a Community Setting. Cancer care for the whole patient: meeting psychosocial health needs. Washington: The National Academies Press; 2008.
50. Geiger AM, West CN, Nekhlyudov L, Herrinton LJ, Liu IA, Altschuler A, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006; 24: 1350-6.
51. Rolnick S, Altschuler A, Nekhlydov L, Elmore JG, Greene SM, Harris EL, et al. What women wish they knew before prophylactic mastectomy. Cancer Nursing. 2007; 30: 1-7.
52. Nekhlyudov L, Bower M, Herrinton LJ, Altschuler A, Greene SM, Rolnick S, et al. Women's decision-making roles regarding contralateral prophylactic mastectomy. J Natl Cancer Inst Monogr. 2005; 35: 55-60.
53. Krouse RS, Herrinton LJ, Grant M, Wendel CS, Green SB, Mohler MJ, et al. Health-related quality of life among long-term rectal cancer survivors with an ostomy: manifestations by sex. J Clin Oncol. 2009; 27: 4664-70.
54. Altschuler A, Ramirez M, Grant M, Wendel C, Hornbrook MC, Herrinton L, et al. The influence of husbands 'or male partners' support on women's psychosocial adjustment to having an ostomy resulting from colorectal cancer. J Wound Ostomy Continence Nurs. 2009; 36: 299-305.
55. Liu L, Herrinton LJ, Hornbrook MC, Wendel CS, Grant M, Krouse RS. Early and late complications among long-term colorectal cancer survivors with ostomy or anastomosis. Dis Colon Rectum. 2010; 53: 200-12.
56. McMullen CK, Wasserman J, Altschuler A, Grant ML, Hornbrook MC, Liljestrand P, et al. Untreated peristomal skin complications among long-term colorectal cancer survivors with ostomies. Clin J Oncol Nurs. 2011; 15: 644-50.
57. Grant M, McMullen CK, Altschuler A, Mohler MJ, Hornbrook MC, Herrinton LJ, et al. Gender differences in quality of life among long-term colorectal cancer survivors with ostomies. Oncol Nurs Forum. 2011; 38(5): 587-96. Oncol Nurs Forum 2011; 38: 587-96.
58. Mazor KM, Roblin DW, Greene SM, Lemay CA, Firneno CL, Calvi J, et al. Toward patient-centered cancer care: patient perceptions of problematic events, impact, and response. J Clin Oncol 2012. J Clin Oncol 2012; Apr 16 [Epub ahead of print].
59. Mazor KM, Greene SM, Roblin D, Lemay CA, Firneno CL, Calvi J, et al. More than words: patients' views on apology and disclosure when things go wrong in cancer care. Patient Educ Couns. 2011. doi: 10. 1016/j. pec. 2011. 07. 010.
60. Gustafson DH, Hawkins R, Boberg E, Pingree S, Serlin RE, et al. Impact of a patient-centered, computer-based health information/support system. Am J Prev Med. 1999; 16: 1-9.
61. McTavish FM, Gustafson DH, Owens BH, Hawkins RP, Pingree S, Wise M, et al. CHESS (Comprehensive Health Enhancement Support System): an interactive computer system for women with breast cancer piloted with an underserved population. J Ambul Care Manage. 1995; 18: 35-41.
62. Epstein RM, Street RL, Jr. Patient-centered communication in cancer care: Promoting healing and reducing suffering. National Cancer Institute 2007; No. 07-6225.
63. Aiello Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012; 104: 1293-305.
64. Oeffinger KC, van Leeuwen FE, Hodgson DC. Methods to assess adverse health-related outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2022-34.
65. Aiello EJ, Buist DS, Wagner EH, Tuzzio L, Greene SM, Lamerato LE, et al. Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research Network. Breast Cancer Res Treat. 2008; 107: 397-403.
66. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. J Clin Oncol. 2010; 28: 4120-8.
67. Nekhlyudov L, Li L, Ross-Degnan D, Wagner AK. Five-year patterns of adjuvant hormonal therapy use, persistence, and adherence among insured women with early-stage breast cancer. Breast Cancer Res Treat. 2011; 130: 681-9.
68. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011; 126: 529-37.
69. Kwan ML, Weltzien E, Kushi LH, Castillo A, Slattery ML, Caan BJ. Dietary patterns and breast cancer recurrence and survival among women with early-stage breast cancer. J Clin Oncol. 2009; 27: 919-26.
70. Kwan ML, Abrosone CB, Lee MM, Barlow J, Krathwohl SE, Ergas IJ, et al. The Pathways Study: a prospective study of breast cancer survivorship within Kaiser Permanente Northern California. Cancer Causes Control. 2008; 10: 1065-76.
71. Bhatia S. Role of genetic susceptibility in development of treatment-related adverse outcomes in cancer survivors. Cancer Epidemiol Biomarkers Prev. 2011; 20: 2048-67.